ISMAILI NABIL

Directeur de spécialité d'oncologie médicale et de radiothérapie, UM6SS, HUICK, HUIM6 chez UM6SS, HUICK, HUIM6

[ISMAILI NABIL @ISMAILIN1978]

https://t.co/smPeiqnOPH

[ISMAILI NABIL @ISMAILIN1978]

https://t.co/NhmrnzFHAS

[ISMAILI NABIL @ISMAILIN1978]

https://t.co/smPeiqnOPH

[Biomedicines MDPI @Biomed_MDPI]

A new systematic review in Biomedicines synthesizes landmark GynecologicOncology advances covering new immunotherapy standards & biomarker-driven care
https://t.co/rmFes5JVDP

[Frontiers - Endocrinology @FrontEndocrinol]

New Research: Redefining standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025 https://t.co/kOmGUpoPb1 #FrontiersIn #Endocrinology

[ISMAILI NABIL @ISMAILIN1978]

Delighted to share my latest publication in @ExpertRev_Antic!
📄 ESMO 2025 and new therapies in breast cancer: does society always benefit?
A critical overview of practice-changing data from ESMO-2025
🔗 https://t.co/JJcQKcudNN

[ISMAILI NABIL @ISMAILIN1978]

🎉 Thrilled to share my new publication in @ExpertRev_Antic !
📄 ESMO 2025 and new therapies in breast cancer: does society always benefit?
From adjuvant CDK4/6 inhibitors to ADCs & biomarker-driven strategies—while reflecting on cost, equity & societal impact.

[ISMAILI NABIL @ISMAILIN1978]

This commentary highlights the critical findings by Huang and He on HER2 overexpression in upper tract urothelial carcinoma and contextualizes them within the paradigm-shifting results of the phase 3 RC48-C016 trial, now published in The New England Journal of Medicine.

[ISMAILI NABIL @ISMAILIN1978]

Nabil Ismaili: Recent Data are Shifting the Historical Paradigm https://t.co/SL8vdQCh7j

[ISMAILI NABIL @ISMAILIN1978]

https://t.co/SS9YlQWIeG

[ISMAILI NABIL @ISMAILIN1978]

📢 I warmly invite you to submit your original research, reviews, or clinical studies to this Special Issue.
Focus is on:
✅Novel therapeutic agents (ADCs, immunotherapy, targeted therapy)
✅Biomarkers
✅Molecular pathology of breast cancer. @IJMS_MDPI https://t.co/YBI8sZqPyD

[ISMAILI NABIL @ISMAILIN1978]

Efficacy and Safety of Neoadjuvant Immunotherapy in Non-Metastatic dMMR Colorectal Cancer. https://t.co/GN6xNlFczh

[ISMAILI NABIL @ISMAILIN1978]

Selected phase Ill randomized trials of new strategies in Gynaecological cancers presented at the ASCO/ESMO 2025 Annual Meeting or published in high impact journals; @Biomed_MDPI . https://t.co/ByU4xMlqet

[ISMAILI NABIL @ISMAILIN1978]

Selected phase Ill randomized trials of new strategies in breast cancer presented at the ASCO 2025 Annual Meeting. https://t.co/m1sq5tG45i

[ISMAILI NABIL @ISMAILIN1978]

Precision medicine goes proactive in metastatic HR+/HER2- breast cancer. 🧬🩸
The 2025 algorithm is built on:
1. Baseline biomarkers (ESR1, PIK3CA).
2. Dynamic ctDNA monitoring (SERENA-6).
3. Targeted switches at mutation emergence. https://t.co/3mLXfZCrFE

[ISMAILI NABIL @ISMAILIN1978]

First-line metastatic TNBC is now an ADC game. 💥
PD-L1 ineligible? TROP2-ADCs are your new standard.
🔹 Sacituzumab govitecan (ASCENT-03): PFS HR=0.62
🔹 Datopotamab deruxtecan (BEGONIA): ORR 79%
Biomarker testing (PD-L1, gBRCA) is the key to entry. https://t.co/3mLXfZCrFE

[ISMAILI NABIL @ISMAILIN1978]

Metastatic HER2+ breast cancer: A new treatment sequence for 2025.
1L: T-DXd + Pertuzumab sets a new PFS benchmark (~40 months!) (DESTINY-Breast09).
Maintenance: Add Tucatinib post-induction (HER2CLIMB-05). https://t.co/3mLXfZCrFE

[ISMAILI NABIL @ISMAILIN1978]

TNBC treatment is now highly biomarker-driven. ✅
Neoadjuvant: Chemo + IO + Carboplatin is the backbone.
Adjuvant: Residual disease?
➡️ gBRCA mut? → Olaparib
➡️ gBRCA wt? → Capecitabine
Long-term survival is the goal. (GeparNuevo, KEYNOTE-522 updates). https://t.co/3mLXfZCrFE

[ISMAILI NABIL @ISMAILIN1978]

TNBC treatment is now highly biomarker-driven. ✅
Neoadjuvant: Chemo + IO + Carboplatin is the backbone.
Adjuvant: Residual disease?
➡️ gBRCA mut? → Olaparib
➡️ gBRCA wt? → Capecitabine
Long-term survival is the goal. (GeparNuevo, KEYNOTE-522 updates). https://t.co/3mLXfZCrFE

[ISMAILI NABIL @ISMAILIN1978]

The HER2+ early breast cancer algorithm has a new powerhouse: Trastuzumab Deruxtecan (T-DXd). ✨
🔹 Neoadjuvant: T-DXd→THP boosts pCR (DESTINY-Breast11).
🔹 Adjuvant: For residual disease, T-DXd beats T-DM1 with a 53% risk reduction (DESTINY-Breast05). https://t.co/3mLXfZCrFE